Viridian Therapeutics (VRDN) announced a preliminary balance of approximately $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The figure is unaudited and subject to completion of financial closing procedures, and the company’s independent auditor has not performed any review or assurance work on this number. The final amount reported in the upcoming unaudited condensed consolidated balance sheet may differ materially.
Viridian Therapeutics, Inc. files an S-3ASR prospectus supplement describing its pipeline and offering mechanics. The company highlights lead programs including veligrotug (an intravenous anti-IGF-1R monoclonal antibody) and VRDN-003 (a planned low-volume, subcutaneous anti-IGF-1R intended for at-home auto-injector use for TED). The filing states VRDN-006 and VRDN-008 are engineered FcRn inhibitors. Stated timelines include VRDN-006 proof-of-concept IgG reduction data in Q3 2025, an anticipated IND submission for VRDN-008 by end of 2025, and anticipated VRDN-003 topline REVEAL-1 and REVEAL-2 data in H1 2026. As of September 3, 2025 the company had 81,668,033 common shares outstanding, 134,864 Series A and 145,160 Series B preferred shares. Use of proceeds is for development, commercialization preparation, working capital and general corporate purposes. The Registration Rights Agreement requires Viridian to use commercially reasonable efforts to register certain shares and explicitly does not include demand or piggyback registration rights.
Viridian Therapeutics (VRDN) filed an 8-K to disclose a collaboration and license agreement signed 30 Jul 2025 with Japan-based Kissei Pharmaceutical covering two IGF-1R monoclonal antibodies, veligrotug and VRDN-003, for thyroid eye disease and other potential indications in Japan. Kissei receives exclusive Japanese development and commercialization rights and a limited non-exclusive manufacturing right; Viridian retains global rights elsewhere and will supply product.
Financial terms: Kissei will pay $70 million upfront. Viridian is eligible for up to $315 million in development, regulatory and sales milestones. Tiered royalties in the low-20% to mid-30% range on future Japanese sales will follow launch. Kissei funds Japanese clinical, regulatory and commercial activities under joint-steering oversight, reducing Viridian’s cash burden.
Strategic impact: The agreement delivers immediate, non-dilutive capital, extends cash runway and externally validates VRDN-003/veligrotug while preserving all ex-Japan upside. Key execution risks include dependence on Kissei’s development success and Viridian’s ongoing manufacturing obligations.